leep apnea occurs in . 50% of patients with endstage renal disease (ESRD), [1] [2] [3] [4] [5] [6] which is considerably higher than in the general population. 7 In contrast to the extensive ESRD literature, few studies have investigated the prevalence of sleep apnea in patients with nondialysis-dependent chronic kidney disease (CKD). These studies have been limited by small sample size, selective recruitment, lack of appropriate comparison groups, and equivocal defi nitions of sleep apnea and CKD, and no single study, to our knowledge, has evaluated patients with the full spectrum of kidney function. [8] [9] [10] [11] [12] The coexistence of sleep apnea in patients with CKD and ESRD is likely to have clinical relevance.
and heart rate variability, a pressure transducer to record nasal airfl ow, a microphone to record snoring, and a body position sensor. The oximeter provided the data for an automated scoring algorithm, which calculated the respiratory disturbance index (RDI) based on the number of episodes of oxyhemoglobin desaturation Ն 4% per hour of monitoring. Nocturnal oxygen saturation was sampled at 1 Hz. The Remmers Sleep Recorder was validated by comparison with attended polysomnography. 29, 30 We defi ned sleep apnea as an RDI Ն 15 because this refl ects mod erately severe sleep apnea that is likely to be clinically sig nifi cant. 31, 32 The Remmers Sleep Recorder has a sensitivity of 98% and specifi city of 88% for a designation criteria of RDI Ն 15. 30 A sleep medicine physician (P. J. H.) blinded to the patients' kidney function reviewed the raw data, confi rmed that the estimated RDI was accurate, and determined whether apnea was central (CheyneStokes respiration [CSR] ) or obstructive (obstructive sleep apnea [OSA] ) based on the morphology of the airfl ow recordings. Nasal pressure recordings with a characteristic crescendo/decrescendo pattern and no evidence of airfl ow limitation were classifi ed as CSR, whereas recordings without a crescendo/decrescendo pattern and with airfl ow limitation were classifi ed as OSA ( Fig 1 ) . Nocturnal hypoxia was defi ned as an Sa o 2 , 90% for Ն 12% of monitoring, which has previously been used in the Sleep Heart Health Study. 33 If the nocturnal cardiopulmonary monitoring test was nondiagnostic (patient did not sleep, unsatisfactory technical quality, or short monitoring time), the test was repeated. If the test remained nondiagnostic or was declined, it was classifi ed as inconclusive, and the patient was excluded from further analysis. Patients with a previously completed sleep study, prior diagnosis of sleep apnea, or treatment with CPAP were included if their diagnostic sleep study was available for review and their eGFR was known at the time of the sleep study.
Statistical Analysis
Data are reported as mean Ϯ SD for continuous variables and median (range) for categorical and nonnormally distributed variables. Parametric and nonparametric tests were used when appropriate. The unpaired t test or the Mann-Whitney U test was used for comparisons between two groups, whereas the one-way anal ysis of variance or the Kruskal-Wallis test was used for comparison among three groups. The Jonckheere-Terpstra test was used to examine trends among nonnormally distributed continuous variables. Categorical comparisons were analyzed using the x 2 test and Fisher exact test. Univariate and multivariate logistic regression models were used to identify the factors associated with sleep apnea and nocturnal hypoxia. Traditional risk factors for sleep apnea (age, male sex, BMI, neck circumference, history of cardiovascular disease, cerebrovascular disease, diabetes, sedatives, and antidepressants) and kidney function status (eGFR Ն 60, CKD, ESRD) were included. For nocturnal hypoxia, COPD and RDI were added to these variables. The Hosmer-Lemeshow goodnessof-fi t test and omnibus tests of model coeffi cients were used to test the model fi t for the logistic regression models. These tests demonstrated that the models were sensitive to differences in kidney function groups and that there was an adequate fi t of the data to the model. All statistical analyses were two sided with a .05 sig nifi cance level and were performed using SPSS version 17.0 (SPSS Inc) software.
Results

Patient Recruitment
A total of 403 patients (eGFR Ն 60, n 5 87; CKD, n 5 185; ESRD, n 5 132) were recruited ( Fig 2 ) ; have been proposed to reduce kidney function 20, 21, 23 ) or directly through the effect of hypoxia on the kidney. 25, 26 We sought to determine, through a cross-sectional study design, the prevalence of sleep apnea and nocturnal hypoxia in patients with CKD and to con fi rm the reported high prevalence of sleep apnea in patients with ESRD. We hypothesized that patients with CKD and ESRD have an increased prevalence of sleep apnea, which increases as kidney function declines.
Materials and Methods
Patient Selection and Recruitment
Adult patients (aged Ն 18 years) attending outpatient nephrology clinics and hemodialysis units were invited to participate in the study. Exclusion criteria included supplemental oxygen use, tracheostomy, and inability to give informed consent. The study was approved by the University of Calgary Conjoint Health Research Ethics Board (E#20091). Informed consent was obtained from all participants in accordance with the Declaration of Helsinki.
Patients were stratifi ed according to their estimated glomerular fi ltration rate (eGFR) at the time of the study visit and classifi ed into three groups based on the National Kidney Foundation staging system as follows: eGFR Ն 60 mL/min/1.73 m 2 , CKD (eGFR , 60 mL/min/1.73 m 2 ), and ESRD (on hemodialysis). 27 eGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. 28 All patients completed a questionnaire that surveyed for demo graphic information; sleep and medical history, including hypertension, congestive heart failure, coronary artery disease (angina, myocardial infarction, and coronary artery bypass surgery), cerebrovascular disease (stroke or transient ischemic attack), diabetes, and COPD; and medication use. Medications included sedatives (benzodiazepines and hypnotics), antidepressants, and narcotics.
Sleep Apnea and Nocturnal Hypoxia
Patients performed an unattended, overnight cardiopulmo nary monitoring study at home (Remmers Sleep Recorder Model 4.2; SagaTech Electronics Inc). Dialysis patients were asked to perform the overnight study on a dialysis-free day. The monitor consisted of an oximeter to record arterial oxygen saturation (Sa o 2 ) Manuscript received July 20, 2011; revision accepted December 1, 2011.
6.4 Ϯ 2.0 h for patients with ESRD. Furthermore, the proportion of monitoring time that patients reported sleeping was 85.5% Ϯ 12.5% for eGFR Ն 60, 80.7% Ϯ 14.9% for CKD, and 78.1% Ϯ 17.8% for ESRD. Consequently, sleep effi ciency and monitoring time were suffi ciently long to capture important respiratory events ( Fig 3 , Table 3 ).
The proportion of patients with sleep apnea increased as kidney function decreased (eGFR Ն 60, n 5 15 [27%]; CKD, n 5 51 [41%]; ESRD, n 5 43 [57%]; x 2 5 12.019; P 5 .002). Sleep apnea was predominantly obstructive; however, the prevalence of CSR increased as eGFR decreased. The RDI was higher in groups with lower kidney function. Trend analysis 149 did not complete overnight cardiopulmonary monitoring for the following reasons: anxiety, travel dis tance, lack of time (n 5 122); technical diffi culties (n 5 22); and receiving treatment with CPAP (n 5 5). Comparison of the remaining 254 patients (eGFR Ն 60, n 5 55; CKD, n 5 124; ESRD, n 5 75) ( Table 1 ) with the 149 who withdrew showed that those who completed the study were younger men with hypertension and larger neck circumfer ences.
Clinical Profi le
Patients with CKD and ESRD were older than patients with eGFR Ն 60 ( Table 2 ) . BMI also differed across groups. The prevalence of hypertension was . 50% in all patient groups and was significantly higher in those with CKD and ESRD. The prevalence of other comorbidities increased as eGFR declined. There was no difference in the prevalence of antidepressant medications, but sedatives and narcotics were used more frequently as kidney function declined. A history of snoring was reported equally across the three groups (eGFR Ն 60, n 
Sleep Apnea
The mean duration of nocturnal cardiopulmonary monitoring was 6.8 Ϯ 1.5 h for patients with eGFR Ն 60, 7.2 Ϯ 1.5 h for patients with CKD, and Nocturnal hypoxia was found in 9 patients (16%) with eGFR Ն 60, 58 patients (47%) with CKD, and 36 patients (48%) with ESRD ( x 2 5 17.328, P , .001) ( Fig 4 , Table 3 ). Trend analysis indicated a signifi cant increase in the duration of Sa o 2 , 90% as kidney function declined ( P 5 .004).
Regression Analysis
Univariate logistic regression for sleep apnea revealed that ESRD, advanced age, male sex, increased BMI, increased neck circumference, congestive heart failure, coronary artery disease, and diabetes were associated with sleep apnea ( Table 4 ) . Multivariate analysis revealed that ESRD, advanced age, increased BMI, and increased neck circumference were associated with sleep apnea (Nagelkerke R 2 , 0.400) ( Table 4 ) .
Univariate analyses for nocturnal hypoxia revealed that CKD, ESRD, advanced age, increased BMI, increased neck circumference, congestive heart failure, coronary artery disease, cerebrovascular disease, diabetes, COPD, and RDI were signifi cant predictors of nocturnal hypoxia ( Table 4 ). Multivariate analysis indicated that CKD, COPD, and RDI were signifi cant predictors of increased risk for nocturnal hypoxia, with RDI being the strongest (Nagelkerke R 2 , 0.480) ( Table 4 ) . ESRD, advanced age, and increased BMI were of borderline signifi cance. Exclu sion of the 14 patients who completed a polysomnography test instead of home cardiopulmonary monitoring did not alter the results. indicated a signifi cant increase in RDI as kidney function declined ( P , .001).
Nocturnal Hypoxia
The proportion of patients who experienced nocturnal hypoxia increased as eGFR decreased ( Fig 4 ) . The present study addressed several of these limitations. First, we examined patients with the full spec trum of kidney function, ranging from those with eGFR Ն 60 to ESRD. Second, all patients were recruited from nephrology clinics and hemodialysis units, including those with minimally impaired kidney function (eGFR . 60), which we believe is the most appropriate control group for this study. The high prevalence of sleep apnea in this group likely refl ects the fact that the patients comprised a referred pop ulation with a high prevalence of hypertension and other renal symptoms. Third, patients were not excluded by age, sex, comorbidities, or medications, improving the generalizability of the fi ndings to the CKD and ESRD populations. Comparison of the present ESRD population to a cohort of 237 patients with ESRD from the Southern Alberta Renal Program showed a similar clinical profi le. 37 The present CKD population also had a similar clinical profi le to the Chronic Renal Insuffi ciency Cohort study. 38 Consequently, we believe that the present study population is representative of the general CKD and ESRD populations. In addition, we determined eGFR using the CKD-EPI equation, which provides a more reliable classifi cation of patients with an eGFR Ն 60. 28, 36 
Discussion
We found that the prevalence and severity of sleep apnea increased as kidney function declined. Furthermore, sleep apnea is common in patients with CKD in addition to those with ESRD. We also found a high prevalence of nocturnal hypoxia in patients with CKD and ESRD that appeared to be due to both sleep apnea and additional nonapneic factors.
Previous studies have evaluated the prevalence of sleep apnea in CKD. Markou et al 10 reported a 31.4% prevalence of sleep apnea in a cross-sectional study of 35 patients with CKD, but their study was limited by a small sample size and the absence of comparative groups with eGFR Ն 60 and ESRD. Further, patients with cardiovascular disease were excluded, limiting the generalizability of their fi ndings because cardiovascular comorbidities are common in this patient population. 19, 23 Sim et al 12 reported an increased risk for sleep apnea in patients with mildly reduced eGFR. However, the prevalence of sleep apnea was low (2.5%), and the absence of BMI data precluded 40, 41 have been proposed to cause sleep apnea in patients with ESRD. It is possible that similar mechanisms contribute to the pathogenesis of sleep apnea in patients with CKD prior to starting dialysis. A striking fi nding was the high prevalence of nocturnal hypoxia in patients with CKD that was similar to that seen in patients with ESRD. Further more, only a portion of the nocturnal hypoxia in the CKD and ESRD groups was attributed to sleep apnea, suggesting that the pathogenesis was partly due to nonapneic factors. Two possible mechanisms are Among traditional risk factors, advanced age, increased BMI, increased neck circumference, cardio vascular disease, and diabetes were all associated with sleep apnea. Additionally, kidney disease status Finally, we cannot comment on causality because of the cross-sectional nature of the study.
In conclusion, we have identifi ed that patients with CKD are commonly exposed to nocturnal hypoxia related to both unrecognized sleep apnea and other factors. Nocturnal hypoxia has the potential to alter important clinical outcomes in this patient population, such as long-term cardiovascular risk and the rate of decline in kidney function. Further studies are required to determine whether treatment of sleep apnea and nocturnal hypoxia improves these clinical outcomes in patients with CKD.
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Author contributions: Mr Nicholl and Dr Hanly had full access to all of the data in the study and take full responsibility for the integrity of the data and accuracy of the data analysis. Mr Nicholl : contributed to the acquisition, analysis, and interpretation of the data and the drafting of the manuscript. Dr Ahmed : contributed to the acquisition, analysis, and interpretation of the data and reviewed the manuscript for important intellectual content . Dr Loewen : contributed to the conception and design of the study; acquisition, analysis, and interpretation of the data; and reviewed the manuscript for important intellectual content. Dr Hemmelgarn : contributed to the acquisition, analysis, and interpretation of the data; statistical expertise; and reviewed the manuscript for important intellectual content. Ms Sola : contributed to the acquisition, analysis, and interpretation of the data and fi nal approval of the manuscript. Mr Beecroft : contributed to the acquisition, analysis, and interpretation of the data and fi nal approval of the manuscript. Dr Turin : contributed statistical expertise and reviewed the manuscript for important intellectual content. Dr Hanly : contributed to the conception and design of the study; acquisition, analysis, and interpretation of the data; drafting of the manuscript; and study supervision. Financial/nonfi nancial disclosures: The authors have reported to CHEST that no potential confl icts of interest exist with any companies/organizations whose products or services may be discussed in this article . Role of sponsors: The sponsors had no role in the design of the study, the collection and analysis of the data, or in the preparation of the manuscript. comorbid pulmonary and cardiac disease and med ications that can alter the mechanics and control of respiration. [40] [41] [42] [43] Multivariate analysis revealed that COPD was associated with nocturnal hypoxia, but cardiovascular disease and use of sedatives and narcotics were not. Other potential causes, such as fl uid overload, should be considered in future studies. What are the clinical implications of the fi ndings? Sleep apnea increases the risk of hypertension, 14 cardiovascular disease, and cerebrovascular disease, 16, 18 all of which are important and highly prevalent complications of both CKD and ESRD. 19, 22, 23, 37, 38 These complications of sleep apnea are predominantly mediated through nocturnal hypoxia, which has been associated with elevated nocturnal BP, 20 left ventricular hypertrophy, 21 and adverse cardiovascular outcomes in patients with ESRD. 19, 22 Although it is likely that sleep apnea may have a similar impact on clinical outcomes in patients with CKD, to our knowledge, this has not been studied to date. Furthermore, the potential interaction between nocturnal hypoxia and declining kidney function in patients with CKD is even more intriguing. Nocturnal hypoxia has been demonstrated to be independently associated with an increased risk for accelerated loss of kidney function. 44 The chronic hypoxia hypothesis suggests that chronic ischemic damage in the tubulointerstitium of the kidney is the fi nal common pathway for the development of ESRD. 25, 26 If such a process is already under way in patients with CKD, it is possible that ongoing nocturnal hypoxia will amplify the effect and accelerate the decline in kidney function. If so, identifi cation and treatment of nocturnal hypoxia may provide a potential disease-modifying intervention that could delay or halt the progression of CKD to ESRD. Because a history of snoring and unrefreshing sleep were equally common among the three patient groups, objective cardiopulmonary eval uation may be required to identify these respiratory abnormalities.
The present study has a number of strengths. First, we recruited a relatively large sample from a renal pop ulation representative of the general CKD and ESRD populations. Second, we applied the same meth odology to a broad spectrum of kidney disease, ranging from patients with eGFR Ն 60 to ESRD. Third, we determined eGFR using the CKD-EPI equation, which is more reliable than what has been used in previous studies to estimate eGFR Ն 60.
The study also has some limitations. First, the differences in neck size and prevalence of hypertension between the subjects who completed the study and those who withdrew raise the possibility of selection bias, which could result in an overestimation of the prevalence of sleep apnea. We tried to limit this by emphasizing that sleep-related symptoms were not required for recruitment and by using the same
